Contact

Peptide Receptor Radionuclide Therapy as a Two-Step Strategy for Initially Unresectable Liver Disease From Neuroendocrine Tumors: a Single-Center Experience

Costanza Chiapponi et al., Endocrine Surgery (2020) - PMID: 32419082

Product(s) used in this publication:  Specialty Peptides

Abstract

Purpose: In this study, we describe our experience with peptide receptor radionuclide therapy (PRRT) for initially unresectable liver disease as a two-steps therapeutic strategy, first in neoadjuvant intention before surgery and then later on in case of disease relapse.

Methods: We performed a retrospective evaluation of four cases of unresectable liver metastases of NET of different origins treated with neoadjuvant Lu-177-DotaTATE for conversion into resectability first and as rechallenging treatment after disease relapse.

Results: After treatment with Lu-177-DotaTAE, resectability was reached in three of four cases. In one case, SIRT was additionally performed preoperatively. Relapse occurred in three of four cases after 32, 34, and 37 months, respectively, and was managed with Re-PRRT-treatment.

Conclusion: Although more data are needed, our retrospective study suggests that treatment with Lu-177-DotaTATE is an important adjunct to surgery not only in neoadjuvant intention but also for treating disease relapse. A register study might deliver more evidence for supporting this strategy.

Stay in touch and be the first to receive the latest news!